Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge

E-ISSN： 1873-5576|16|8|701-709

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.16, Iss.8, 2016-09, pp. : 701-709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia

By Balakrishnan Kumudha Gandhi Varsha

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 409-423

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions

Current Cancer Drug Targets, Vol. 16, Iss. 8, 2016-10 ,pp. : 710-720

Bentham Science Publishers

Access to resources Recommend Favorite

Pentostatin in chronic lymphocytic leukemia

By Sauter Craig Lamanna Nicole Weiss Mark A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 9, 2008-09 ,pp. : 1217-1222

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine for treatment of chronic lymphocytic leukemia

By Chang Julie Elizabeth Kahl Brad Steven

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1495-1505

Informa Healthcare

Access to resources Recommend Favorite

Lenalidomide in lymphomas and chronic lymphocytic leukemia

By Wiernik Peter H

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 475-488

Informa Healthcare

Access to resources Recommend Favorite